Already under fire from U.S. authorities and others, Indivior faces new legal scrutiny from officials in California. More: Indivior's legal challenges escalate with new Suboxone subpoena from California Source: fierce
read moreWant to get serious about business development? Take a page from Pfizer’s playbook—and that’s exactly what Biogen is doing. On Thursday, the big biotech said it recruited veteran Dan Karp in a revamp of its BD and corporate strategy team.
read moreRecent Chinese approvals of Gardasil and Gardasil 9 have contributed millions of extra dollars to developer Merck & Co.’s top line. They’ve also propelled two Chinese families into Bloomberg’s ranking of the world’s richest people. More: Meet the Gardasil billionaires,
read moreAfter the Trump administration laid out its plan for drug prices, the president says drugmakers are planning “massive drops” in prices. More: Trump says drugmakers plan to offer 'massive drops' in prices—fact or fantasy? Source: fierce
read moreXeljanz is on a roll. The Pfizer immunology blockbuster scored a big new approval in psoriatic arthritis last year, and now it has won an FDA green light to treat ulcerative colitis. Plus, the approval includes the larger 10-mg dose,
read moreAccess to Medicine Foundation warns that urgent action is needed to rebuild the antibiotics market More: Antibiotic supply chains on 'brink of collapse' Source: News
read more© 1994 - 2025 B.M. Pharmaceuticals